Saltar al contenido
Merck

Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis.

Cell reports (2021-12-30)
Nur Yucer, Rodney Ahdoot, Michael J Workman, Alexander H Laperle, Maria S Recouvreux, Kathleen Kurowski, Diana J Naboulsi, Victoria Liang, Ying Qu, Jasmine T Plummer, Simon A Gayther, Sandra Orsulic, Beth Y Karlan, Clive N Svendsen
RESUMEN

Germline pathogenic mutations in BReast CAncer (BRCA1) genes are thought to drive normal fallopian tube epithelial (FTE) cell transformation to high-grade serous ovarian cancer. No human models capture the sequence of events for disease initiation and progression. Here, we generate induced pluripotent stem cells (iPSCs) from healthy individuals and young ovarian cancer patients with germline pathogenic BRCA1 mutations (BRCA1mut). Following differentiation into FTE organoids, BRCA1mut lines exhibit cellular abnormalities consistent with neoplastic transformation compared to controls. BRCA1mut organoids show an increased production of cancer-specific proteins and survival following transplantation into mice. Organoids from women with the most aggressive ovarian cancer show the greatest pathology, indicating the potential value to predict clinical severity prior to disease onset. These human FTE organoids from BRCA1mut carriers provide a faithful physiological in vitro model of FTE lesion generation and early carcinogenesis. This platform can be used for personalized mechanistic and drug screening studies.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
MS-SAFE Protease and Phosphatase Inhibitor
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad
Sigma-Aldrich
Anti-OVGP1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad